Antipseudomonal Beta-Lactams: Piperacillin-Tazobactam, Cefepime, Ceftazidime, Meropenem, and Ceftolozane-Tazobactam in Practice
A clinician-facing pharmacology playbook for the five workhorse antipseudomonal beta-lactams: spectrum, resistance enzymology (AmpC, ESBL, KPC, MBL, OXA-48), pharmacokinetics, extended-infusion dosing, renal adjustment, and the role of new agents (ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam) in MDR Pseudomonas.
Executive Summary
S1. Microbiology of P. aeruginosa & Resistance Mechanisms
Pseudomonas aeruginosa is a non-fermenting Gram-negative bacillus characterised by intrinsic resistance to many antibiotic classes, an exceptional capacity to acquire additional resistance during therapy, and a predilection for healthcare-associated infections in patients with mechanical ventilation, indwelling lines, prolonged hospitalisation, immunosuppression, structural lung disease (CF, bronchiectasis), and burns. Its resistance armament includes outer membrane porin loss (reducing carbapenem entry), efflux pump overexpression (MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY-OprM), and beta-lactamase production:
- AmpC (chromosomal) — present in nearly all P. aeruginosa; can be derepressed during therapy with weak inducers (cefepime is stable, but ceftazidime selects for derepressed mutants)
- Extended-spectrum beta-lactamases (ESBL: TEM, SHV, CTX-M) — uncommon in Pseudomonas vs Klebsiella/E. coli
- Klebsiella pneumoniae carbapenemase (KPC) — Class A serine carbapenemase; treated with ceftazidime-avibactam or meropenem-vaborbactam
- Metallo-beta-lactamase (MBL: VIM, IMP, NDM) — Class B zinc-dependent; resistant to all penicillins, cephalosporins, and carbapenems; treat with cefiderocol or aztreonam-avibactam combinations
- OXA-48-type — Class D oxacillinase; partial carbapenem hydrolysis; treat with ceftazidime-avibactam
Multi-drug resistant definitions
| Term | Definition |
|---|---|
| MDR (multi-drug resistant) | Non-susceptible to ≥1 agent in ≥3 of: piperacillin, ceftazidime/cefepime, carbapenems, fluoroquinolones, aminoglycosides |
| XDR (extensively drug resistant) | Non-susceptible to ≥1 agent in all but ≤2 antibiotic categories |
| PDR (pan-drug resistant) | Non-susceptible to all agents in all antibiotic categories |
| DTR (difficult-to-treat resistant) | Resistant to all standard beta-lactams (piperacillin-tazo, cefepime, ceftazidime, meropenem, imipenem) AND fluoroquinolones |
Pseudomonas aeruginosa is intrinsically resistant to many antibiotics due to four overlapping resistance mechanisms that all contribute simultaneously: (1) low outer membrane permeability from reduced porin OprD (drives carbapenem resistance, especially meropenem); (2) efflux pumps (MexAB-OprM, MexCD-OprJ, MexXY-OprM) that export multiple antibiotic classes; (3) chromosomal AmpC beta-lactamase derepression that inactivates penicillins and most cephalosporins (cefepime is stable); (4) acquired resistance genes on plasmids — ESBL, KPC/NDM/VIM/IMP carbapenemases, plasmid-mediated AmpC. Difficult-to-treat resistant (DTR) Pseudomonas, defined as resistance to all standard first-line beta-lactams plus fluoroquinolones, occurs in 1-5% of clinical isolates in most hospitals but exceeds 15-20% in some ICU populations.
Resistance patterns differ by infection site and patient population: hospital-acquired pneumonia and VAP carry highest MDR risk; cystic fibrosis chronic lung infection has its own resistance ecosystem driven by lifetime antibiotic exposure; nosocomial bloodstream infection from intravascular devices tends to be more susceptible than respiratory or wound isolates. Local antibiogram data should drive empiric selection — Pseudomonas susceptibility varies dramatically by institution and unit.
S2. Drug-by-Drug Comparison
| Drug | Class | Standard adult dose (CrCl >50) | Notable features |
|---|---|---|---|
| Piperacillin-tazobactam | Penicillin/BLI | 4.5 g IV q6–8h (extended 4-h infusion) | Anaerobes, GBS; loses ESBL coverage at high inoculum |
| Cefepime | 4th-gen cephalosporin | 2 g IV q8h (extended infusion preferred) | AmpC-stable; CNS penetration; neurotoxicity risk in renal failure |
| Ceftazidime | 3rd-gen cephalosporin | 2 g IV q8h | AmpC inducer; loses Gram+ coverage; melioidosis |
| Meropenem | Carbapenem | 1–2 g IV q8h | Broadest spectrum; CNS approved; reserve to preserve activity |
| Imipenem-cilastatin | Carbapenem | 500 mg–1 g IV q6–8h | Seizure risk, especially in renal failure or epilepsy |
| Aztreonam | Monobactam | 2 g IV q8h | Pseudomonas only; safe in penicillin allergy; ESBL & MBL resistant |
| Ceftolozane-tazobactam | 5th-gen cephalosporin/BLI | 1.5–3 g IV q8h (3 g for HAP/VAP) | MDR Pseudomonas; no anaerobe coverage |
| Ceftazidime-avibactam | 3rd-gen ceph/BLI | 2.5 g IV q8h | KPC, OXA-48; not MBL/IMP/NDM |
| Meropenem-vaborbactam | Carbapenem/BLI | 4 g IV q8h | KPC; not MBL or AmpC |
| Imipenem-relebactam | Carbapenem/BLI | 1.25 g IV q6h | KPC, AmpC; not MBL |
| Cefiderocol | Siderophore cephalosporin | 2 g IV q8h (3-h infusion) | MBL Pseudomonas; trojan-horse Fe transport; mortality concerns in some HAP/VAP studies |
Piperacillin-tazobactam vs cefepime — the most common decision
| Feature | Pip-tazo | Cefepime |
|---|---|---|
| Anaerobe coverage | Yes (B. fragilis) | No (need metronidazole) |
| Enterococcus faecalis | Yes | No |
| Listeria | Some activity | No |
| AmpC stability (Enterobacter, Serratia, Citrobacter) | Susceptible to AmpC induction | Stable |
| ESBL high-inoculum | Loses activity | Loses activity |
| CNS penetration | Poor | Good |
| AKI signal in combination | ~10–15% AKI when paired with vancomycin | No major synergistic AKI signal |
| Cost / availability | Inexpensive, widely available | Inexpensive, widely available |
S3. PK/PD Principles & Extended Infusion Dosing
Beta-lactam antibacterial activity is time-dependent: efficacy correlates with the percentage of the dosing interval during which the free drug concentration exceeds the MIC of the pathogen (%fT>MIC). For maximal bactericidal effect against Pseudomonas, 50–70% fT>MIC is the target; against critical infections (HAP/VAP, neutropenic fever, bacteraemia), some clinicians target 100% fT>MIC.
Extended-infusion piperacillin-tazobactam
Standard 30-minute infusion of pip-tazo achieves 50% fT>MIC at MIC = 4 mg/L but fails at MIC = 16 (the susceptibility breakpoint). Switching to 4-hour extended infusion of 3.375 g q8h infused over 4 hours increases fT>MIC dramatically and has been associated with reduced mortality in critically ill patients with Pseudomonas (DALI 2014, BLING-III 2024). This is now the standard of care in many ICUs for HAP/VAP, septic shock, and bacteraemia. Loading dose (2.25 g over 30 min) is given before the first 4-hour infusion.
Continuous infusion
For meropenem, cefepime, and ceftazidime, continuous infusion (24-hour infusion of total daily dose after a loading dose) achieves >90% fT>MIC and may further improve outcomes in deep-seated infection. Stability is the limit — meropenem is stable for 4–6 hours at room temperature in saline, requiring multiple bag changes per day; pip-tazo is stable for ~24 hours.
Renal adjustment
| Drug | CrCl >50 | CrCl 30–50 | CrCl 10–30 | CrCl <10 / HD |
|---|---|---|---|---|
| Pip-tazo | 4.5 g q6–8h | 3.375 g q6h | 2.25 g q6h | 2.25 g q8h + 0.75 g after HD |
| Cefepime | 2 g q8h | 2 g q12h | 2 g q24h | 1 g q24h + dose after HD |
| Ceftazidime | 2 g q8h | 2 g q12h | 2 g q24h | 1 g q24h + dose after HD |
| Meropenem | 1–2 g q8h | 1 g q8h | 1 g q12h | 500 mg q24h + dose after HD |
| Aztreonam | 2 g q8h | 1 g q8h | 500 mg q8h | 500 mg q12h |
| Ceftolozane-tazo | 1.5 g q8h | 750 mg q8h | 375 mg q8h | 150 mg q8h + load 500 mg |
S4. Empiric Selection Algorithm
Empiric coverage indications
| Clinical scenario | Preferred empiric agent | Rationale |
|---|---|---|
| HAP/VAP | Pip-tazo OR cefepime + vancomycin/linezolid + (consider 2nd Pseudomonas agent if high MDR risk) | Coverage for Pseudomonas, MRSA, Gram-negatives |
| Neutropenic fever | Cefepime monotherapy OR pip-tazo OR meropenem; add vancomycin if line-related/skin source | Broad Gram-negative coverage; cefepime preferred for AmpC organisms |
| Septic shock from unknown source | Pip-tazo + vancomycin (consider meropenem if recent ESBL exposure) | Time-to-effective therapy <1 hour |
| Complicated UTI / pyelonephritis with risk factors for Pseudomonas | Pip-tazo, cefepime, ceftazidime, or meropenem (depending on prior antibiograms) | Stratify by recent antibiotic exposure, healthcare contact |
| Complicated intra-abdominal infection | Pip-tazo (anaerobe coverage built-in) | Polymicrobial; covers anaerobes without need for metronidazole |
| Bacterial meningitis with Gram-negative concern (postoperative, head trauma) | Meropenem (CNS-approved) or cefepime (CNS-active) | Pip-tazo and ceftazidime have inferior CNS penetration |
| Cystic fibrosis exacerbation | Combination Pseudomonas therapy: pip-tazo or meropenem + tobramycin (per local sensitivities) | Synergy + double coverage given high resistance rates in chronic colonisation |
| Suspected ESBL Enterobacterales | Meropenem (or ertapenem if no Pseudomonas concern) | Carbapenem-stable; pip-tazo failures in MERINO trial 2018 |
| AmpC organisms (Enterobacter, Citrobacter freundii, Serratia, Providencia) | Cefepime, meropenem; AVOID ceftriaxone, ceftazidime, pip-tazo for serious infection | AmpC derepression on therapy |
Empiric selection rests on three risk factors: (1) likelihood of Pseudomonas infection (hospital-acquired, ICU, prior gram-negative infection, structural lung disease, neutropenia, recent broad-spectrum antibiotic exposure); (2) local antibiogram pattern and ESBL/MDR prevalence; (3) severity of illness (sepsis, septic shock, organ failure). For septic shock with possible Pseudomonas, the empiric default is meropenem 2 g IV q8h extended infusion (over 3-4 hours) plus an aminoglycoside (tobramycin 7 mg/kg daily) for the first 48 hours, narrowing to monotherapy once cultures return. For lower-severity hospital-acquired infection with low MDR risk, cefepime 2 g IV q8h extended infusion is the preferred choice — narrower spectrum than meropenem, lower C. difficile risk than pip-tazo, and stable against the chromosomal AmpC that affects Enterobacter and Citrobacter.
Piperacillin-tazobactam 4.5 g IV q8h extended infusion remains a workhorse for intra-abdominal sepsis and skin/soft tissue infections with Pseudomonas risk where anaerobic coverage is also valued. Ceftazidime 2 g IV q8h is used less in modern practice because of its lack of gram-positive coverage and concerns about resistance development on monotherapy. The “MERINO” trial caution about pip-tazo vs meropenem for ESBL bacteremia does not directly transfer to Pseudomonas empiric coverage — local ESBL prevalence guides whether to start with pip-tazo or escalate directly to meropenem.
S5. MDR Pseudomonas & the New Agents
| Resistance pattern | Preferred agent | Alternative |
|---|---|---|
| MDR Pseudomonas (porin loss + AmpC + efflux), carbapenemase-negative | Ceftolozane-tazobactam 3 g q8h (HAP/VAP) | Ceftazidime-avibactam, imipenem-relebactam |
| KPC carbapenemase | Ceftazidime-avibactam 2.5 g q8h | Meropenem-vaborbactam, imipenem-relebactam |
| OXA-48 carbapenemase | Ceftazidime-avibactam | Cefiderocol |
| Metallo-beta-lactamase (NDM, VIM, IMP) | Cefiderocol 2 g q8h OR aztreonam-avibactam (combination ceftazidime-avibactam + aztreonam) | Polymyxin combinations as last resort |
| Difficult-to-treat resistant (DTR) Pseudomonas | Ceftolozane-tazobactam OR ceftazidime-avibactam (depending on mechanism) | Cefiderocol if both fail |
Diagnostic workflow for resistance characterisation
- Routine MIC (broth microdilution) for piperacillin-tazo, cefepime, ceftazidime, meropenem
- If carbapenem-resistant: phenotypic carbapenemase test (modified Hodge, Carba NP, mCIM)
- If carbapenemase-positive: molecular identification (KPC, OXA-48, NDM, VIM, IMP) by PCR or rapid commercial assay (BioFire FilmArray Pneumonia panel)
- Targeted MIC testing for new agents (ceftolozane-tazo, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol) — not on routine sensitivity panels at most centres
- Consult Infectious Diseases for any DTR or carbapenemase-positive isolate
Stewardship considerations
Carbapenem use should be carefully justified — every meropenem dose selects for carbapenemase production and increases the population-level prevalence of these resistance genes. Strategies:
- De-escalate from carbapenem to narrower beta-lactam once susceptibilities allow
- Use ertapenem (no Pseudomonas activity, no ICU/serious infection role) when ESBL coverage required without Pseudomonas concern
- Reserve ceftolozane-tazobactam, ceftazidime-avibactam for confirmed need (susceptibility data, ID consultation)
- Avoid empiric carbapenem when pip-tazo, cefepime, or ceftazidime cover the suspected organisms
- Source control (drain abscess, remove infected device) is at least as important as antibiotic choice
For difficult-to-treat resistant (DTR) Pseudomonas — resistance to piperacillin-tazobactam, cefepime, ceftazidime, meropenem, ciprofloxacin, AND levofloxacin — new beta-lactam-beta-lactamase inhibitor combinations have transformed management. Ceftolozane-tazobactam (Zerbaxa) 1.5 g IV q8h (3 g q8h for pneumonia) is highly active against AmpC- and porin-mediated resistant Pseudomonas; it is first-line for confirmed DTR Pseudomonas in nosocomial pneumonia and is preferred over polymyxin-based regimens. Ceftazidime-avibactam (Avycaz) 2.5 g IV q8h covers KPC, OXA-48, and AmpC mechanisms; useful for KPC-producing Pseudomonas and combination resistance patterns. Imipenem-relebactam (Recarbrio) 1.25 g IV q6h covers KPC and some AmpC-derepressed strains. Cefiderocol (Fetroja) 2 g IV q8h is a siderophore cephalosporin active against most carbapenem-resistant Pseudomonas including metallo-beta-lactamase producers — reserved for the most resistant cases.
Polymyxins (colistin, polymyxin B) have moved from frontline to last-resort agents for DTR Pseudomonas given availability of cleaner new agents; nephrotoxicity rates of 30-50% and inferior PK/PD attainment make them inferior to ceftolozane-tazobactam when both are available. Aminoglycoside (tobramycin, amikacin) monotherapy is inappropriate for serious Pseudomonas infections but adjunctive use for the first 48 hours of septic shock until cultures return is reasonable. ID consultation is mandatory for all DTR Pseudomonas cases — both for antibiotic optimization and for infection control measures.
Practice Insights: Extended Infusion, Cefepime First-Line, and Reserving Carbapenems
Extended Infusion Beats Standard Infusion for Time-Dependent Beta-Lactams
in experienced hands, the single highest-impact dosing change is extended infusion of beta-lactams (3-4 hour infusion rather than 30-minute bolus). Beta-lactams are time-dependent killers — efficacy correlates with the fraction of dosing interval that drug concentration exceeds MIC (fT>MIC). For isolates with MIC near the susceptibility breakpoint (the situation in most clinically meaningful Pseudomonas infections), 30-minute infusion struggles to maintain fT>MIC above 50-60%; 3-4 hour infusion achieves it reliably. The standard for piperacillin-tazobactam 4.5 g q8h, cefepime 2 g q8h, and meropenem 1-2 g q8h is extended infusion in any patient with sepsis, suspected high-MIC organism, or critical illness. Mortality benefit in septic shock from meta-analyses is real, particularly for higher-MIC isolates.
Cefepime Is the Cleaner Empiric First-Line
For empiric coverage of nosocomial gram-negative infection with possible Pseudomonas where anaerobic coverage is not needed (most non-intra-abdominal infections), cefepime 2 g IV q8h extended infusion is the preferred first-line. Three advantages over piperacillin-tazobactam: (1) lower C. difficile risk (narrower anaerobic effect); (2) stable against chromosomal AmpC that compromises ceftriaxone and to some extent pip-tazo in Enterobacter/Citrobacter/Serratia infections; (3) does not have the MERINO trial concerns about ESBL bacteremia coverage. The historical concern about cefepime neurotoxicity in renal failure is real but mitigated by appropriate renal dosing (1-2 g q24h for CrCl <10).
Carbapenems Are Reserve, Not Reflex
In practice, meropenem and imipenem are reserved for: septic shock with broad empiric coverage need, known ESBL-producing Enterobacterales bacteremia, suspected ESBL/AmpC mixed infection, or documented resistance to first-line agents. Reflex meropenem for routine pneumonia or UTI in stable patients drives Pseudomonas carbapenem resistance and Klebsiella KPC emergence at the institutional level. Once empiric meropenem is started, de-escalation to cefepime or pip-tazo at 48-72 hours when cultures and susceptibilities clarify is essential — and frequently missed in the consultation experience. The single biggest stewardship intervention is reviewing carbapenems at 72 hours and asking whether the patient still needs one.
DTR Pseudomonas Gets Ceftolozane-Tazobactam, Not Polymyxin
For difficult-to-treat resistant (DTR) Pseudomonas — resistance to all standard antipseudomonal beta-lactams plus fluoroquinolones — ceftolozane-tazobactam (Zerbaxa) at 3 g IV q8h for pneumonia or 1.5 g q8h for other sites is the first-line. The IDSA 2024 guidance and experienced practice support this choice over polymyxin-based regimens given lower nephrotoxicity (30-50% with colistin vs 5-10% with ceftolozane-tazobactam) and better PK/PD attainment. For KPC-producing or metallo-beta-lactamase-producing strains, ceftazidime-avibactam, cefiderocol, or imipenem-relebactam depending on the specific resistance mechanism. ID consult mandatory.
Illustrative Scenario
A patient in their fifties with hematologic malignancy on chemotherapy was admitted with neutropenic fever and progressive hypotension. Empiric cefepime 2 g IV q8h was started; blood cultures grew Pseudomonas aeruginosa at 36 hours with cefepime MIC 8 (susceptible but near breakpoint), meropenem MIC 1. The patient was not improving despite cefepime, with persistent fever, rising vasopressor requirement, and increasing oxygen need. On ID consult the treating clinicians switched to meropenem 2 g IV q8h extended infusion (3-hour infusion) plus tobramycin 7 mg/kg daily for the first 48 hours given septic shock physiology, MIC near breakpoint on cefepime, and high-stakes situation. The patient stabilized clinically by hour 24 after the switch, vasopressors weaned over the next 48 hours, and tobramycin was stopped at hour 48. Meropenem was continued for 14 days; surveillance cultures cleared by hour 72.
Practice Pattern Refinements vs Standard Algorithm
- Extended-infusion beta-lactam (3-4 hours) for septic shock and high-MIC isolates. Pip-tazo 4.5 g q8h, cefepime 2 g q8h, meropenem 1-2 g q8h. Achieves fT>MIC targets reliably; mortality benefit in meta-analyses for septic shock and high-MIC organisms.
- Cefepime as preferred empiric over pip-tazo when anaerobic coverage is not needed. Lower C. difficile risk, AmpC stability, no MERINO-trial concerns. Pip-tazo remains preferred for intra-abdominal sepsis where anaerobic coverage matters.
- Carbapenems are reserve agents, with mandatory 72-hour stewardship review. Reflex meropenem drives institutional resistance. De-escalate to cefepime or pip-tazo at 48-72 hours when cultures permit. Continued meropenem past 72 hours requires explicit justification.
- DTR Pseudomonas: ceftolozane-tazobactam, not polymyxin. Lower nephrotoxicity, better PK/PD, mortality data support new BL-BLI combinations over colistin. ID consult mandatory; choice of new agent depends on specific resistance mechanism (KPC vs MBL vs OXA-48).
S6. Pearls, Pitfalls & FAQ
Frequently Asked Questions
Ceftolozane-tazobactam is reserved for confirmed multidrug-resistant Pseudomonas (DTR Pseudomonas), suspected MDR risk based on prior cultures from the same patient, or settings with very high MDR rates >25%. It is not first-line empiric therapy because: (1) it lacks anaerobic coverage (no B. fragilis), (2) it has no Enterococcus activity, (3) it does not cover Acinetobacter, and (4) its cost is roughly 20–30× standard pip-tazo. The 2024 IDSA Pseudomonas guidance restricts ceftolozane-tazobactam (or ceftazidime-avibactam, or imipenem-relebactam) to documented or strongly suspected DTR Pseudomonas after standard agents have failed or are demonstrated resistant. Prior pip-tazo failure is not by itself an indication — increase the dose, switch to extended infusion, or change to cefepime first.
Yes, but limited. Empiric combination therapy is reasonable for: severe sepsis or septic shock from suspected Pseudomonas where MDR rate is high; patients with high-risk healthcare exposure or known prior MDR Pseudomonas colonisation; cystic fibrosis pulmonary exacerbation where high inoculum and biofilm contribute to relative resistance; and Pseudomonas endocarditis (rare but typically requires combination therapy throughout). Once susceptibilities return and the isolate is fully susceptible to the beta-lactam, de-escalate to monotherapy — no mortality benefit from continued combination therapy in susceptible isolates and increased nephrotoxicity from continued aminoglycoside. The MERINO trial (JAMA 2018) actually showed worse outcomes with pip-tazo vs meropenem for ESBL bacteraemia, but did not change Pseudomonas combination therapy paradigms.
Meropenem and imipenem cross the Pseudomonas outer membrane through the OprD porin and have intrinsic activity at clinically achievable concentrations. Ertapenem is too large and too anionic to efficiently cross OprD, so it has poor Pseudomonas activity (MICs typically >16 mg/L). Ertapenem also lacks Acinetobacter activity. The clinical implication: for patients with potential Pseudomonas infection, ertapenem is the wrong carbapenem — use meropenem or imipenem. Conversely, when ESBL Enterobacteriaceae coverage is needed without Pseudomonas concern (e.g., complicated UTI in a previously healthy patient), ertapenem is preferred because of its convenient daily dosing (1 g IV q24h), more limited spectrum (less collateral damage), and good ICU/non-ICU pharmacokinetics.
For confirmed severe IgE-mediated penicillin allergy (anaphylaxis, hypotension, urticaria), the safest Pseudomonas-active agent is aztreonam (a monobactam with minimal beta-lactam ring cross-reactivity with penicillins or most cephalosporins). Note one important caveat — aztreonam is structurally similar to ceftazidime, so cross-reactivity has been documented in some cases of severe ceftazidime allergy; if there is documented anaphylaxis to ceftazidime specifically, use a carbapenem (meropenem) instead. For severe penicillin allergy where Pseudomonas + Gram-positive cocci coverage is needed (HAP), the regimen is aztreonam + vancomycin + metronidazole (for anaerobes if intra-abdominal concern) — though formal allergy testing or skin-test reconciliation should be done electively when the situation allows. Carbapenems are generally tolerated in penicillin-allergic patients without prior carbapenem reaction (cross-reactivity ~1%).
Cefepime neurotoxicity (encephalopathy, myoclonus, non-convulsive status epilepticus, aphasia) occurs in 1–10% of patients on cefepime, with risk concentrated in: CrCl <60 (drug accumulates with inadequate renal adjustment), age >70, total daily dose >4 g, prior CNS disease (stroke, dementia, epilepsy), and concurrent CNS-active drugs. Onset is typically 2–7 days into therapy. Recognition requires a high index of suspicion in any patient on cefepime with new altered mental status — check renal dosing first, then obtain EEG (often non-convulsive status), and consider neurology consultation. The condition is reversible within 48–72 hours of dose reduction or discontinuation. To prevent: always cap cefepime at the renally-adjusted dose (e.g., 1 g q24h for CrCl 10–30); avoid 2 g q8h dosing in patients with even moderate renal impairment.
- Antiviral Therapy for Herpesviruses: Acyclovir, Valacyclovir, Ganciclovir, Foscarnet
- Fluoroquinolones: Black Box Risks, Restricted Indications, and Appropriate Use
- Sacubitril-Valsartan (ARNI): Initiation, Titration, and Monitoring in HFrEF
- IL-23 Inhibitors: Risankizumab, Guselkumab, Tildrakizumab in Psoriasis, PsA, and IBD
- GP IIb/IIIa Inhibitors: Clinical Pharmacology of Abciximab, Eptifibatide, Tirofiban
- Unfractionated Heparin: Dosing, Monitoring, and Reversal